🌐 Cell and Gene Therapies: New Perspectives on Access to Innovative Treatments 🌐
📜 Today, we’re sharing one of the latest publications from the New England Journal of Medicine, exploring the new access model for cell and gene therapies for Medicare and Medicaid beneficiaries. This is a crucial topic for the future of public healthcare in the United States, with important global implications.
💉 What you’ll find in this study:
•How the U.S. government is working to reduce the costs of innovative therapies.
•A focus on treatments for sickle cell disease (SCD) and the effectiveness of current therapies.
•Outcome-based payment models: paying only if the treatment proves effective.
📊 Why this matters: With treatment costs reaching $2-3 million or more, the future of universal access depends on new management and negotiation strategies.
💬 What do you think about outcome-based payment models? Could they be adopted in other countries as well? Share your thoughts in the comments!
#InnovativeMedicine #GeneTherapies #CellTherapy #PublicHealthcare #SCD #Medicare #Medicaid #AccessToCare #HealthcareInnovation
